Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Sentynl-Therapeutics

More Like This

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

PR Newswire associated0

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Sanofi responds to NICE negative FAD of olipudase alfa

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

PR Newswire associated0

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

First product based on LTS Sorrel™ wearable drug delivery platform launched in the US

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility